Conducting analysis according to Lipinski's 5-criteria rule and predicting pharmacokinetic-toxicological parameters, we obtained one compound with drug-like properties is Pityriacitrin B. Therefore, this compound has the potential to develop into drugs that inhibit ER-α receptors for breast cancer treatment.